miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

Abstract

MicroRNAs (miRNAs) are short noncoding RNA molecules, which posttranscriptionally regulate genes expression and play crucial roles in diverse biological processes, such as development, differentiation, apoptosis and proliferation. Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines. We found that miR‐181b was downregulated in both multidrug‐resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug‐resistant human lung cancer cell line A549/cisplatin (CDDP), and the downregulation of miR‐181b in SGC7901/VCR and A549/CDDP cells was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. In vitro drug sensitivity assay demonstrated that overexpression of miR‐181b sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively. The luciferase activity of a BCL2 3′‐untranslated region‐based reporter construct in SGC7901/VCR and A549/CDDP cells suggests that a new target site in the 3′UTR of BCL2 of the mature miR‐181s (miR‐181a, miR‐181b, miR‐181c and miR‐181d) was found. Enforced miR‐181b expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR‐induced and CDDP‐induced apoptosis, respectively. Taken together, our findings suggest that miR‐181b could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part, by modulation of apoptosis via targeting BCL2.